Texas NeuroAIDS Research Center

摘要 此申请是为了补充桥梁资金，以维持德州神经艾滋病的运作 研究中心（TNRC）的一段时间（U24 MH 10093010）。该项目招募艾滋病毒阳性 病人，他们的特点医学和神经心理学，进行尸检时， 适当的，保持一个人类标本库，并在世界范围内分发标本。的 本合作协议U24第5财政年度的资金将于2023年2月28日结束。到了这次 写程序是在一个无成本的扩展和一个挂起的“进位”请求相结合的情况下进行的 尚未核准的前几年的“远期”资金。申请继续资助 美国国立卫生研究院正在审查。据联邦官员说， 在未来将不知道大约六个月后，从年底的U24。创造了 “资金缺口”。根据联邦官员的建议，我们正在申请补充桥梁 资金，以维持正常运作，直到长期资金的决定是由美国国立卫生研究院发布。我们 建议申请将允许运营到2023年8月31日的资金， 大约六个月的正常运作，从时间的U24结束。我们申请过桥资金 这段时间的计算方式是由NIH建议的。我们已经从我们的请求中减去了 两个潜在的可用资金来源：1）可用于核准的零费用的余额 延期; 2）与待决的未支用资金结转请求相对应的单独数额 前几年的资金。假设这两个请求都得到了NIH的批准和颁布， 我们计算了到2023年9月1日运营所需的额外资金。的 这一数额反映在我们的预算请求及其理由中。要求提供补充资金， 维持运作，直至为该项目提供资金的长期计划明确为止。

Abstract This application is for supplemental bridge funding to maintain operation of the Texas NeuroAIDS Research Center (TNRC) for a brief period of time (U24MH10093010). This project recruits HIV positive patients, characterizes them medically and neuropsychologically, performs autopsies when appropriate, maintains a human specimen repository, and distributes specimens worldwide. The funding for fiscal year 5 of this cooperative agreement U24 was to end on February 28, 2023. As of this writing the program is operating on a no cost extension combined with a pending request for “carry forward” funds from prior years that has not yet been approved. The application for continued funding via contracting is under a review by the NIH. According to federal officials the decision regarding funding in the future will not be known for approximately six months from the end of the U24. That has created a “funding gap.” Following the advice of federal officials, we are applying for supplemental bridge funding to maintain normal operations until a decision on long term funds is issued by the NIH. We were advised to apply for funds that will allow operation through August 31, 2023, which amounts to roughly six months of normal operation from the time the U24 was to end. Our request for bridge funds for that period is calculated in a manner suggested by the NIH. We have subtracted from our request two sources of potentially available funds: 1) the balance that was available for an approved no cost extension, and 2) a separate amount corresponding to a pending request for carry forward of unspent funds from prior years. Assuming that these two requests are both approved and enacted by the NIH, we calculated an amount of additional funds necessary to operate through September 1, 2023. That amount is reflected in our budget request and its justification. Supplemental funding is requested to maintain operation until the long-term plan for funding the project become clear.